Show results for
  • Sygnature
  • News
  • Drug Discovery
  • Therapeutic Areas
  • Events
  • Vacancies

Bioscience

Our in-depth knowledge of target biology, therapeutic area specialism, and experience of working collaboratively at each stage of the drug discovery pipeline allows the efficient design and implementation of tailored high-quality assays, which help to accelerate your drug discovery programs.

Our team is staffed by highly experienced scientists (81% PhDs), many with 10-20 years of drug discovery experience gained in pharmaceutical research, (AstraZeneca, Takeda, GSK, Merck, Novartis, Pfizer and Prosidion).  More than 25% of the department has over 15 years’ first-hand industry experience in discovering new drugs, both small molecules and biologicals across a broad range of therapeutic areas and biological target classes.  Your drug discovery projects are in safe hands at Sygnature Discovery.

  • We can assist you in screening your novel compounds for a range of project-specific properties, such as cellular function and isolated target engagement characteristics.
  • Utilise the very latest technologies to minimise the risk of drug failure later in the drug discovery pipeline.
  • Offer a broad spectrum of adaptable capabilities to help you reach success with your drug discovery target in a variety of therapeutic areas.

We pride ourselves in delivering high-quality consistent assay data to measure Structure-Activity Relationships (SAR) and define compound Mechanism of Action (MOA) to help drive your project forward.  All project data linked to experimental write-ups are stored within a powerful online Dotmatics-based web portal that gives secure access to your biological data regardless of your geographical location.

Sygnature Discovery’s Bioscience Department forms part of the talented Integrated Drug Discovery team that can enhance your drug discovery project at any stage of the process.  You will benefit from being able to access bench bioscientists directly and our scientists work collaboratively to address scientific needs so that your drug discovery program is given the best opportunity for success.

We have established a broad range of industry-standard in-house capabilities which, complemented by cutting-edge technology platforms and supported by our in-depth drug discovery expertise, allow us to add value to your drug discovery program. Our team is continually enhancing the suite of capabilities available to you, mirroring the evolving discovery landscape, always ensuring that the technical expertise and drug discovery know-how underpin each of our platforms.

Bioscience Services

In Vivo Pharmacology

RenaSci provides an integrated blend of consultancy and experimental services to clients from all sectors of the pharmaceutical industry to help maximise research productivity and streamline drug development. The company was established in 2001 and specialises in the following key areas: Abuse & Dependence CNS Obesity Diabetes NASH & Kidney Disease Their clients include pharma,...
View Article

DISCOVER

Primary Tissues

Sygnature Discovery has Human Tissue Act (HTA) accreditation, an internal blood donor panel and access to human and animal primary tissues from accredited biobanks and commercial vendors to provide physiologically relevant support to your project.

DISCOVER

Biomarker Discovery

Sygnature Discovery have a diverse range of sensitive biomarker detection platforms and assays that can be used to develop and validate biomarkers for your drug target.

DISCOVER

Biophysical Assays

Our biophysicists are able to employ the latest technologies to characterise compound binding interactions at all stages of drug discovery.

DISCOVER

Biochemical Assays

Sygnature offers a tailored biochemical assay development service utilising multiple assay formats in order to provide assays most relevant to your drug discovery venture.

DISCOVER

Cellular Assays

Sygnature can provide you with 2D and 3D cellular assays providing real-time and high-resolution end points to assess the impact of your target on multiple phenotypic endpoints.Capabilities include live cell imaging, high content imaging and flow cytometry, using a variety of primary and immortalised cell types.

DISCOVER

Screening

Sygnature provides a range of scalable hit identifications creening methodologies from high-content to fragment screens. Bespoke, efficient screening assays can be developed to support discovery programs in a wide variety of therapeutic areas.

DISCOVER

Assay Development

We design, implement and maintain your project-tailored in vitro screening cascades based on decades of experience, providing assay development services from Target Validation through to Lead Optimisation and candidate nomination.

DISCOVER

Get in Touch

For more details on how we can provide innovative support to your project please use this contact form.

CTA Form

The information you supply will be processed in accordance with the General Data Protection Regulation (EU) 2016/679. For further details about how Sygnature Discovery collects, uses and stores personal data, please refer to our Website Privacy Notice available here.